SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Anthropic

Anthropic is currently trending as investors monitor its high-profile legal battle with federal agencies over military AI usage and the company's preparations for a highly anticipated IPO. Community discussion is heavily centered on the startup's multi-billion dollar compute deals, its rivalry with OpenAI, and the broader debate regarding the security implications of its advanced models.

Symbotic, Inc. is an automation technology company, which engages in a robotics and automation-based product movement technology platform. It focuses on developing, commercializing, and deploying innovative, end-to-end technology solutions for supply chain operations. It operates through the United States and Canada geographical segments. The company was founded by Richard B. Cohen on December 11, 2020 and is headquartered in Wilmington, MA.

Symbotic Inc - Ordinary Shares - Class A

Symbotic Inc 

Symbotic is facing intense scrutiny as investors weigh its massive $22B contracted backlog against concerns regarding heavy customer concentration, insider selling, and high-valuation execution risk. The community remains deeply divided, with bulls pointing to the company's long-term warehouse automation dominance and multi-year revenue visibility, while bears focus on recent equity offerings and the challenges of scaling hardware-heavy deployments.

OpenAI

OpenAI is trending as investors digest a strategic shift in capital expenditure and a potential IPO timeline as the company navigates intensifying competition from Anthropic and rising scrutiny over its massive infrastructure spending. The community remains highly polarized, with many debating the sustainability of current AI business models versus the long-term utility of the company's expanding agentic ecosystem.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is seeing increased community chatter as traders react to anticipation surrounding the upcoming Goliath mainnet launch. While some investors are accumulating in hopes of institutional adoption, others remain skeptical, citing historical price volatility and recurring cycles of skepticism within the community.

Ardelyx, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Its products include IBSRELA and XPHOZAH. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending as investors weigh potential M&A speculation against a long-awaited court ruling on Medicare reimbursement for XPHOZAH. While management focuses on long-term IBSRELA growth and profitability, the community remains divided between those frustrated by share price stagnation and those accumulating shares, betting that current valuations overlook future growth and potential catalysts.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Regencell Bioscience is drawing significant attention as community members anticipate a repeat of past parabolic moves, fueled by reports of extremely high borrow fees, scarce available shares for shorting, and a tightly held float. While some investors are bullish on a potential technical breakout above key resistance levels, others remain skeptical, citing ongoing concerns about the company's valuation, lack of revenue, and its involvement in active securities class-action litigation.

Themes ETF Trust - Leverage Shares 2X Long BBAI Daily ETF

Leverage Shares 2X Long BBAI Daily ETF

Investors are actively debating the merits of holding the 2X leveraged BAIG ETF versus the underlying BigBear.ai stock, with many community members focusing on volatility decay and the potential for magnified gains during market swings. The discussion is heavily polarized by varying strategies, ranging from long-term accumulation to aggressive short-term trading and speculation around future catalysts.

Select Sector SPDR Trust (The) - State Street Health Care Select Sector SPDR ETF

Health Care Select Sector SPDR Fund

The healthcare sector is seeing significant inflows as investors rotate into defensive names, with the $XLV tracking toward all-time highs behind a surge in institutional accumulation. Community discussion is focused on the sector's relative strength and its role as a stable hedge, particularly as major pharma names drive index performance while biotech continues to exhibit high-conviction breakout setups.

Nasdaq, Inc. is a holding company, which engages in trading, clearing, exchange technology, regulatory, securities listing, information, and public and private company services. It operates through the following segments: Capital Access Platforms, Financial Technology, and Market Services. The Capital Access Platforms segment delivers liquidity, transparency, and integrity to the corporate issuer and investment community by empowering clients to effectively navigate the capital markets, achieve their sustainability goals, and drive governance excellence. The Financial Technology segment offers platforms that improve the liquidity, transparency, and integrity of the global economy by architecting and operating the markets. The Market Services segment includes equity derivative trading and clearing, cash equity trading, fixed income, currency, and commodities trading. The company was founded by Gordon S. Macklin in 1971 and is headquartered in New York, NY.

Nasdaq Inc - Ordinary Shares - 144A

Nasdaq Inc

Nasdaq Inc. is attracting intense investor attention as algorithmic market makers, institutional dark pools, and high-frequency trading behaviors dominate the order book, fueling community concerns that the platform now reflects a rigged system. Traders are actively debating whether these structural market forces, combined with speculative volatility and ongoing regulatory discussions, are suppressing fair price discovery for the broader tech sector.

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Gilead Sciences, Inc.

Gilead Sciences is trending as the company expands its oncology and immunology portfolio through strategic acquisitions and positive clinical trial readouts for its HIV treatment pipeline. The community is actively discussing the potential for long-term growth driven by these pipeline advancements and strong cash flow, alongside significant institutional interest in the company's valuation as it continues to diversify beyond its core antiviral business.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Do Options Traders Know Something About Adherex Technologies Stock We Don't?

Investors need to pay close attention to FENC stock based on the movements in the options market lately. 

Adherex Technologies Inc. (FENC) Beats Q1 Earnings and Revenue Estimates

Adherex Technologies (FENC) delivered earnings and revenue surprises of +157.14% and +8.36%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates

MaxCyte (MXCT) delivered earnings and revenue surprises of +57.90% and +31.31%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Lags Revenue Estimates

Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of 0.00% and -7.36%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Adherex Technologies (FENC) Expected to Announce Quarterly Earnings on Tuesday

Adherex Technologies (NASDAQ:FENC) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-fennec-pharmaceuticals-inc-stock...

Insider Selling: Adherex Technologies (NASDAQ:FENC) Director Sells 10,781 Shares of Stock

Adherex Technologies Inc. (NASDAQ:FENC - Get Free Report) Director Rosty Raykov sold 10,781 shares of the business's stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $6.47, for a total value of $69,753.07. Following the sale, the director owned...

Adherex Technologies Inc. (NASDAQ:FENC) Given Consensus Recommendation of "Moderate Buy" by Analysts

Shares of Adherex Technologies Inc. (NASDAQ:FENC - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven research firms that are presently covering the stock...

Fennec Pharmaceuticals (TSE:FRX) Stock Price Passes Below Fifty Day Moving Average - Here's What Happened

Fennec Pharmaceuticals (TSE:FRX) Stock Passes Below Fifty Day Moving Average - What's Next...

Adherex Technologies (NASDAQ:FENC) Given "Outperform" Rating at Wedbush

Wedbush reiterated an "outperform" rating and issued a $13.00 target price on shares of Adherex Technologies in a research note on Thursday...

Fennec Pharmaceuticals (TSE:FRX) Shares Cross Below Fifty Day Moving Average   - What's Next?

Fennec Pharmaceuticals (TSE:FRX) Shares Cross Below Fifty Day Moving Average - Here's What Happened...

Fennec Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on the development and commercialization of PEDMARK to reduce the risk of platinum-induced ototoxicity in pediatric patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.

Fennec Pharmaceuticals Inc

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$11.02
Prev Close	$10.55
Open	$10.56
Dividend Yield	0.00%
50-Day Moving Average	$8.34
Beta	1.01
Avg. Volume	377,577.32
PE Ratio	-35.62

52-Week High	$10.59
52-Week Low	$5.65
Market Capitalization	$382.8M
EPS (Annual)	-$0.3409
Price to Book	9.67
Revenue Per Employee	$1.28M

Feed

News

Sentiment

Earnings

Fundamentals

Info

FENCFennec Pharmaceuticals Inc

Latest FENC News